Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.02.017 ◽

2018 ◽

Vol 13 (5) ◽

pp. e84-e85

Author(s):

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted Oncology ◽

10.1007/s11523-015-0387-4 ◽

2015 ◽

Vol 11 (2) ◽

pp. 167-174 ◽

Cited By ~ 10

Author(s):

J. B. Auliac ◽

C. Fournier ◽

C. Audigier Valette ◽

M. Perol ◽

A. Bizieux ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Tyrosine Kinase Inhibitor Therapy ◽

Egfr Mutated

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1126 ◽

2019 ◽

Vol 25 (22) ◽

pp. 6644-6652 ◽

Cited By ~ 18

Author(s):

Jhanelle E. Gray ◽

Isamu Okamoto ◽

Virote Sriuranpong ◽

Johan Vansteenkiste ◽

Fumio Imamura ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutated ◽

First Line Treatment

CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

Value in Health ◽

10.1016/j.jval.2018.09.016 ◽

2018 ◽

Vol 21 ◽

pp. S3

Author(s):

M.S. Holleman ◽

M.J. Al ◽

C.A. Uyl-de Groot

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges

Journal of Thoracic Disease ◽

10.21037/jtd.2017.09.67 ◽

2017 ◽

Vol 9 (9) ◽

pp. 3385-3393 ◽

Cited By ~ 5

Author(s):

Bing Xia ◽

Shirong Zhang ◽

Shenglin Ma

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e31829f684a ◽

2013 ◽

Vol 8 (9) ◽

pp. 1148-1155 ◽

Cited By ~ 66

Author(s):

Victor H.F. Lee ◽

Vicky P.C. Tin ◽

Tim-shing Choy ◽

Ka-on Lam ◽

Cheuk-wai Choi ◽

...

Keyword(s):

Lung Cancer ◽

Treatment Outcome ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Exon 19

Re-biopsy for advanced non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy: CT characteristics of patients with T790M mutation and the use of various re-biopsy procedures

Annals of Oncology ◽

10.1093/annonc/mdx091.023 ◽

2017 ◽

Vol 28 ◽

pp. ii37-ii38

Author(s):

H.J. Koo ◽

M.Y. Kim ◽

C.-M. Choi ◽

J.C. Lee ◽

S. Park

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

T790m Mutation ◽

Abstract B34: Overcoming resistance to EGFR-Tyrosine Kinase Inhibitor therapy in non-small cell lung cancer

Clinical Cancer Research ◽

10.1158/1078-0432.12aacriaslc-b34 ◽

2012 ◽

Vol 18 (3 Supplement) ◽

pp. B34-B34

Author(s):

Rafael Sierra ◽

Anderson Chang ◽

Jason Moffat ◽

Benjamin G. Neel ◽

Ming-Sound Tsao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

Abstract 1232: Overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

10.1158/1538-7445.am2012-1232 ◽

2012 ◽

Author(s):

J Rafael Sierra ◽

Anderson Chang ◽

Jason Moffat ◽

Benjamin G. Neel ◽

Ming-Sound Tsao

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽